TECHNION ISRAEL ANNOUNCES ANTI-ANTHRAX ANTIBIOTIC

The Technion Israel Institute of Technology claims to have developed an antibiotic agent capable of attacking anthrax bacteria at the same time as tackling the toxic proteins released by the bacteria into an infected person's bloodstream. The new agent could become the basis of an anti-anthrax drug in the future.

Pharmaceutical expenditure in Israel is equal to 1.1% of GDP, although domestic research continues to suffer from under-investment. As the process of modernisation continues, with healthcare awareness growing and access to medicines improving, so expenditure levels should increase. Steady economic performance, with real GDP growth climbing steadily, should underpin market growth as overall spending power increases.